Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 101–200 of 1,005
Sibbing, D., Aradi, D., Jacobshagen, C., Gross, L., Trenk, D., Geisler, T., Orban, M., Hadamitzky, M., Merkely, B., Kiss, R. G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32155-4 · Cited by 615
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Kim, B.-K., Hong, S.-J., Cho, Y.-H., Yun, K. H., Kim, Y. H., Suh, Y., Cho, J. Y., Her, A.-Y., Cho, S., Jeon, D. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.7580 · Cited by 588
“Prior myocardial infarction 64 (4) 49 (3)”
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Fox, K. A. A., Clayton, T. C., Damman, P., Pocock, S. J., de Winter, R. J., Tijssen, J. G. P., Lagerqvist, B., & Wallentin, L. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.007 · Cited by 588
Self-citation2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0133 · Cited by 565
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Puymirat, E., Simon, T., Cayla, G., Cottin, Y., Elbaz, M., Coste, P., Lemesle, G., Motreff, P., Popovic, B., Khalife, K., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030798 · Cited by 539
Self-citationSibbing, D., Aradi, D., Alexopoulos, D., ten Berg, J., Bhatt, D. L., Bonello, L., Collet, J.-P., Cuisset, T., Franchi, F., Gross, L., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.03.034 · Cited by 537
“Although this document expands on the recent findings from trials of deescalation, its intent is not to advocate for deescalation of P2Y12-inhibiting therapy routinely in clinical practice, where practitioners should abide, whenever possible, with guideline recommendations (29,32) on the choice of DAPT with highest le…”
BackgroundSelf-citationHeld, C., Åsenblad, N., Bassand, J. P., Becker, R. C., Cannon, C. P., Claeys, M. J., Harrington, R. A., Horrow, J., Husted, S., James, S. K., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.029 · Cited by 541
Self-citationLee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kisor, D. F., Limdi, N. A., Lee, Y. M., Scott, S. A., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2526 · Cited by 519
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
Self-citationTicagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
Johnston, S. C., Amarenco, P., Albers, G. W., Denison, H., Easton, J. D., Evans, S. R., Held, P., Jonasson, J., Minematsu, K., Molina, C. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603060 · Cited by 538
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Gogarten, W., Vandermeulen, E., Van Aken, H., Kozek, S., Llau, J. V., & Samama, C. M. (2010) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32833f6f6f · Cited by 529
Thyroid Hormones and Cardiovascular Function and Diseases
Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., Peeters, R., Zaman, A., & Iervasi, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.045 · Cited by 515
“Recurrent ischemia resulting in adverse CV events following optimal treatment for an acute coronary syndrome occurs in approximately 10% of subjects in randomized controlled trials (RCTs) (2), and this number nearly doubles in real-world registries (3).”
BackgroundSteg, P. G., James, S., Harrington, R. A., Ardissino, D., Becker, R. C., Cannon, C. P., Emanuelsson, H., Finkelstein, A., Husted, S., Katus, H., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.927582 · Cited by 507
Self-citationGarg, S., & Serruys, P. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.007 · Cited by 501
Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02391-6 · Cited by 445
Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.132 · Cited by 484
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 486
2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Pagano, D., Milojevic, M., Meesters, M. I., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx325 · Cited by 481
Lindahl, B., Baron, T., Erlinge, D., Hadziosmanovic, N., Nordenskjöld, A., Gard, A., & Jernberg, T. (2017) · Circulation · doi:10.1161/circulationaha.116.026336 · Cited by 482
Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Lincoff, A. M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.004 · Cited by 479
Primary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476
2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery
Boer, C., Meesters, M. I., Milojevic, M., Benedetto, U., Bolliger, D., von Heymann, C., Jeppsson, A., Koster, A., Osnabrugge, R. L., Ranucci, M., et al. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.06.026 · Cited by 466
“tions is further reduced if a second-generation P2Y12 antagonist (ticagrelor/prasugrel) is used instead of clopidogrel [56, 57], but the risk of both spontaneous and surgical bleeding complications increases with the newer antagonists [56–58].”
BackgroundIbánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
“prasugrel, ticagrelor, or clopidogrel), is recommended in patients with STEMI who are undergoing primary PCI (for up to 12 months).(186,187) Clopidogrel is recommended for 1 month in patients treated with fibrinolysis without subsequent PCI.”
BackgroundInfluentialSelf-citationGénéreux, P., Giustino, G., Witzenbichler, B., Weisz, G., Stuckey, T. D., Rinaldi, M. J., Neumann, F.-J., Metzger, D. C., Henry, T. D., Cox, D. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1323 · Cited by 454
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0243 · Cited by 458
Self-citationJames, S., Angiolillo, D. J., Cornel, J. H., Erlinge, D., Husted, S., Kontny, F., Maya, J., Nicolau, J. C., Spinar, J., Storey, R. F., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq325 · Cited by 446
Self-citationWriting Committee Members, Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., et al. (2010) · Circulation · doi:10.1161/cir.0b013e318202f701 · Cited by 451
Self-citationKulik, A., Ruel, M., Jneid, H., Ferguson, T. B., Hiratzka, L. F., Ikonomidis, J. S., Lopez-Jimenez, F., McNallan, S. M., Patel, M., Roger, V. L., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000182 · Cited by 448
Gurbel, P. A., Bliden, K. P., Butler, K., Antonino, M. J., Wei, C., Teng, R., Rasmussen, L., Storey, R. F., Nielsen, T., Eikelboom, J. W., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.919456 · Cited by 447
Self-citationFiedler, K. A., Maeng, M., Mehilli, J., Schulz-Schüpke, S., Byrne, R. A., Sibbing, D., Hoppmann, P., Schneider, S., Fusaro, M., Ott, I., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.050 · Cited by 443
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434
Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., Held, C., Cannon, C. P., James, S., Pieper, K. S., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.047498 · Cited by 434
Self-citationST-segment elevation myocardial infarction
Vogel, B., Claessen, B. E., Arnold, S. V., Chan, D., Cohen, D. J., Giannitsis, E., Gibson, C. M., Goto, S., Katus, H. A., Kerneis, M., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0090-3 · Cited by 419
Self-citationPereira, N. L., Farkouh, M. E., So, D., Lennon, R., Geller, N., Mathew, V., Bell, M., Bae, J.-H., Jeong, M. H., Chavez, I., et al. (2020) · JAMA · doi:10.1001/jama.2020.12443 · Cited by 424
Wang, S. V., Schneeweiss, S., Initiative, R.-D., Franklin, J. M., Desai, R. J., Feldman, W., Garry, E. M., Glynn, R. J., Lin, K. J., Paik, J., et al. (2023) · JAMA · doi:10.1001/jama.2023.4221 · Cited by 428
Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention
Brar, S. S., ten Berg, J., Marcucci, R., Price, M. J., Valgimigli, M., Kim, H.-S., Patti, G., Breet, N. J., DiSciascio, G., Cuisset, T., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.059 · Cited by 422
Short- and Long-Term Cause of Death in Patients Treated With Primary PCI for STEMI
Pedersen, F., Butrymovich, V., Kelbæk, H., Wachtell, K., Helqvist, S., Kastrup, J., Holmvang, L., Clemmensen, P., Engstrøm, T., Grande, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.037 · Cited by 421
2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0224 · Cited by 418
Vascular Complications of Diabetes
Beckman, J. A., & Creager, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306884 · Cited by 412
Cuisset, T., Deharo, P., Quilici, J., Johnson, T. W., Deffarges, S., Bassez, C., Bonnet, G., Fourcade, L., Mouret, J. P., Lambert, M., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx175 · Cited by 414
“We assumed a 10% occurrence rate of any bleeding or ischaemic complication at 1 year in the switched DAPT group and of 18% in the unchanged DAPT group, based on data from large randomized studies that were available at the time of study design.(1,3,4,10) Based on these assumptions, we calculated that a minimum sample…”
InfluentialAntiplatelet therapies for the treatment of cardiovascular disease
Michelson, A. D. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2957 · Cited by 407
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx334 · Cited by 409
Self-citationSchwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408
Self-citationJames, S., Budaj, A., Aylward, P., Buck, K. K., Cannon, C. P., Cornel, J. H., Harrington, R. A., Horrow, J., Katus, H., Keltai, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.933796 · Cited by 407
Self-citationTicagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA
Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2111749 · Cited by 395
Structure of the human P2Y12 receptor in complex with an antithrombotic drug
Zhang, K., Zhang, J., Gao, Z.-G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paoletta, S., Kiselev, E., Lu, W., et al. (2014) · Nature · doi:10.1038/nature13083 · Cited by 397
Circulating microRNAs as novel biomarkers for platelet activation.
Willeit, P., Zampetaki, A., Dudek, K., Kaudewitz, D., King, A., Kirkby, N. S., Crosby-Nwaobi, R., Prokopi, M., Drozdov, I., Langley, S. R., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300539 · Cited by 365
International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., Sibbing, D., So, D. Y. F., Trenk, D., Alexopoulos, D., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031164 · Cited by 397
Self-citationMalehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398
Alexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., Koutsogiannis, N., Damelou, A., Tsigkas, G., Davlouros, P., et al. (2012) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.112.972323 · Cited by 396
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Sousa-Uva*, M., Head, S. J., Milojevic, M., Collet, J.-P., Landoni, G., Castella, M., Dunning, J., Gudbjartsson, T., Linker, N. J., Sandoval, E., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx314 · Cited by 393
Steg, P. G., Huber, K., Andreotti, F., Arnesen, H., Atar, D., Badimon, L., Bassand, J.-P., De Caterina, R., Eikelboom, J. A., Gulba, D., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr204 · Cited by 395
Self-citationRoberts, J. D., Wells, G. A., Le May, M. R., Labinaz, M., Glover, C., Froeschl, M., Dick, A., Marquis, J.-F., O'Brien, E., Goncalves, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60161-5 · Cited by 391
Therapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 388
Becker, R. C., Bassand, J. P., Budaj, A., Wojdyla, D. M., James, S. K., Cornel, J. H., French, J., Held, C., Horrow, J., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr422 · Cited by 383
Self-citationMega, J. L., Hochholzer, W., Frelinger, A. L., Kluk, M. J., Angiolillo, D. J., Kereiakes, D. J., Isserman, S., Rogers, W. J., Ruff, C. T., Contant, C., et al. (2011) · JAMA · doi:10.1001/jama.2011.1703 · Cited by 383
Self-citationKoushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382
“Long-term treatment with ticagrelor, an antiplatelet medication, reduces cardiovascular events in patients with acute coronary syndrome [177, 178].”
BackgroundCayla, G., Cuisset, T., Silvain, J., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., Bellemain-Appaix, A., Range, G., El Mahmoud, R., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31323-x · Cited by 380
Storey, R. F., Angiolillo, D. J., Patil, S. B., Desai, B., Ecob, R., Husted, S., Emanuelsson, H., Cannon, C. P., Becker, R. C., & Wallentin, L. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.100 · Cited by 373
Self-citationUdell, J. A., Bonaca, M. P., Collet, J.-P., Lincoff, A. M., Kereiakes, D. J., Costa, F., Lee, C. W., Mauri, L., Valgimigli, M., Park, S.-J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv443 · Cited by 370
Ticagrelor in patients with stable coronary disease and diabetes
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908077 · Cited by 365
Self-citationAradi, D., Kirtane, A., Bonello, L., Gurbel, P. A., Tantry, U. S., Huber, K., Freynhofer, M. K., ten Berg, J., Janssen, P., Angiolillo, D. J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv104 · Cited by 367
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M., & Angiolillo, D. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.057 · Cited by 366
“In the 2017 ESC update the topic is covered in greater detail, and 2 CORs are issued: 1 for the early upgrading from clopidogrel to ticagrelor in ACS (COR I, LOE B), as permitted in the PLATO (Platelet inhibition and patient outcomes) trial of ticagrelor (26); and 1 for switching between P2Y12 inhibitors if side-effec…”
Frelinger, A., Michelson, A., & Gremmel, T. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1564835 · Cited by 345
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
“6,7 Lipid-lowering therapies also have proven benefits for patients with AMI.”
BackgroundGilard, M., Barragan, P., Noryani, A. A. L., Noor, H. A., Majwal, T., Hovasse, T., Castellant, P., Schneeberger, M., Maillard, L., Bressolette, E., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.11.008 · Cited by 360
Mechanisms, Consequences, and Prevention of Coronary Graft Failure
Gaudino, M., Antoniades, C., Benedetto, U., Deb, S., Di Franco, A., Di Giammarco, G., Fremes, S., Glineur, D., Grau, J., He, G.-W., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027597 · Cited by 355
2011 Writing Group Members, Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820f2f3e · Cited by 357
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
Nakamura, M., Kimura, K., Kimura, T., Ishihara, M., Otsuka, F., Kozuma, K., Kosuge, M., Shinke, T., Nakagawa, Y., Natsuaki, M., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1109 · Cited by 352
Gimbel, M., Qaderdan, K., Willemsen, L., Hermanides, R., Bergmeijer, T., de Vrey, E., Heestermans, T., Tjon Joe Gin, M., Waalewijn, R., Hofma, S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30325-1 · Cited by 357
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O’Gara, P. T., & Stein, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.013 · Cited by 354
Novel antiplatelet agents in acute coronary syndrome
Franchi, F., & Angiolillo, D. J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.156 · Cited by 353
Steg, P. G., Bhatt, D. L., Hamm, C. W., Stone, G. W., Gibson, C. M., Mahaffey, K. W., Leonardi, S., Liu, T., Skerjanec, S., Day, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61615-3 · Cited by 346
Self-citationWright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.009 · Cited by 342
Levine, G. N., Jeong, Y.-H., Goto, S., Anderson, J. L., Huo, Y., Mega, J. L., Taubert, K., & Smith, S. C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.104 · Cited by 337
Acute Coronary Syndromes: Diagnosis and Management, Part II
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60674-5 · Cited by 336
Self-citationWiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 333
Valgimigli, M., Costa, F., Lokhnygina, Y., Clare, R. M., Wallentin, L., Moliterno, D. J., Armstrong, P. W., White, H. D., Held, C., Aylward, P. E., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw525 · Cited by 330
Self-citation2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m09_01 · Cited by 328
Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Ogita, M., Suwa, S., Isawa, T., Domei, T., Yamaji, K., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.5244 · Cited by 325
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting
Costa, F., Van Klaveren, D., Feres, F., James, S., Räber, L., Pilgrim, T., Hong, M.-K., Kim, H.-S., Colombo, A., Steg, P. G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.048 · Cited by 325
Self-citationAntiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
SIBBING, D., SCHULZ, S., BRAUN, S., MORATH, T., STEGHERR, J., MEHILLI, J., SCHÖMIG, A., VON BECKERATH, N., & KASTRATI, A. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03709.x · Cited by 324
Layland, J., Oldroyd, K. G., Curzen, N., Sood, A., Balachandran, K., Das, R., Junejo, S., Ahmed, N., Lee, M. M. Y., Shaukat, A., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu338 · Cited by 321
Coronary stents: historical development, current status and future directions
Iqbal, J., Gunn, J., & Serruys, P. W. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt009 · Cited by 319
Yannopoulos, D., Bartos, J. A., Raveendran, G., Conterato, M., Frascone, R. J., Trembley, A., John, R., Connett, J., Benditt, D. G., Lurie, K. G., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.059 · Cited by 319
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Self-citationGender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Chew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A., Woodruffe, S., Kerr, A., Branagan, M., & Aylward, P. E. G. (2016) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2016.06.789 · Cited by 314
Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., Kimmel, S. E., McDonough, C. W., Gong, Y., Dave, C. V., et al. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.07.022 · Cited by 313
“discontinuation because of side effects compared with clopidogrel (8).”
BackgroundAtherosclerosis: Successes, Surprises, and Future Challenges
Libby, P., Bornfeldt, K. E., & Tall, A. R. (2016) · Circulation Research · doi:10.1161/circresaha.116.308334 · Cited by 314
Adenosine-Mediated Effects of Ticagrelor
Cattaneo, M., Schulz, R., & Nylander, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.031 · Cited by 312
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 311
Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
Hausenloy, D. J., Barrabes, J. A., Bøtker, H. E., Davidson, S. M., Di Lisa, F., Downey, J., Engstrom, T., Ferdinandy, P., Carbrera-Fuentes, H. A., Heusch, G., et al. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0588-8 · Cited by 308
Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome
Haider, A., Bengs, S., Luu, J., Osto, E., Siller-Matula, J. M., Muka, T., & Gebhard, C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz898 · Cited by 305
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.